CEO to Present on US Investor TV Show and at Biotech Conference
January 10 2018 - 9:00AM
Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased
to advise investors that CEO Dr Jerry Kanellos, was interviewed on
The RedChip Money Report US television program. The interview will
air Wednesday, January 10, at 6 p.m. EST and Sunday, January 14, at
12:30 p.m. EST on American Business TV on The Family Channel,
available in 100 million homes across the U.S., and 10:00 a.m. EST
on The Action Channel.
The interview segment can be viewed at:
youtu.be/Ndd7f2cNaWA.
The RedChip Money Report delivers insightful
commentary on small-cap investing, interviews with Wall Street
analysts, financial book reviews, as well as featured interviews
with executives of public companies. The US TV show is hosted by
David Gentry who is a leading authority on small-cap stocks and the
author of Small Stocks, Big Money, published by Wiley Finance.
Gentry has made multiple guest appearances on both CNBC and Fox
Business News.
Dr Jerry Kanellos, CEO, will also be presenting at 11:30am (WST)
on Tuesday 9th January 2018 at this month’s 10th Annual Biotech
Showcase at the Hilton Hotel in San Francisco, USA. The conference
is always well attended and is an opportunity for companies to
present to, and meet with, representatives from private equity and
institutional investors, potential strategic partners, and large
pharmaceutical companies.
COMPANY
CONTACT: Jerry
KanellosChief Executive Officer (Interim)Ph: +61 (0)3 9824
5254jerrykanellos@immuron.com |
|
AUS INVESTOR RELATIONS:
Peter TaylorNWR CommunicationsPh: +61 (0)4 1203
6231peter@nwrcommunications.com.au |
|
|
|
USA MEDIA CONTACT: Kate
Caruso-SharpeFischTank Marketing and PRUS Ph: + 1 646 699
1414kate@fischtankpr.com |
|
USA INVESTOR RELATIONS:
Jon CunninghamRedChip Companies, Inc.US Ph: +1
(407) 644 4256, (ext. 107)jon@redchip.com |
About RedChip Investor Services:
RedChip is the world leader in investor
relations, financial media, and research for microcap and small-cap
stocks. Founded in 1992, and headquartered in Orlando, Florida,
with affiliates in New York, Pittsburgh, Paris, and Seoul, RedChip
has helped hundreds of companies achieve their capital markets
goals and has been ranked by Inc. Magazine as one of the fastest
growing privately held investor relations firms in the U.S.
RedChip delivers concrete, measurable results
for its clients through its extensive global network of
institutional and retail stock brokers, RIA's, family offices,
investment banks, hedge funds, and accredited investor groups.
Their unique platform combines traditional investor relations
services with multi-media marketing.
ABOUT IMMURON:Immuron Ltd
(ASX:IMC) is a biopharmaceutical company focused on developing and
commercialising oral immunotherapeutics for the treatment of many
gut mediated diseases. Immuron has a unique and safe
technology platform that enables a shorter development therapeutic
cycle. The Company currently markets and sells Travelan® for
the prevention of travellers’ diarrhea whilst its lead product
candidate IMM-124E is in Phase 2 clinical trials for NASH and
ASH. These products together with the Company’s other
preclinical immunotherapy pipeline products targeting
immune-related diseases currently under development, will meet a
large unmet need in the market. For more information visit:
http://www.immuron.com
FORWARD-LOOKING STATEMENTS:This press release
may contain “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts.
Forward-looking statements are based on management’s current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock value. Factors that could cause actual results
to differ materially from those currently anticipated include:
risks relating to our growth strategy; our ability to obtain,
perform under and maintain financing and strategic agreements and
relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to
preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024